

<b>1 PATIENT INFOR</b> (Please complete the following I					
, ,			DOB:	Gender: Male Female	
Address:		City:	Sta	ate: Zip:	
Patient Phone Number:					
	ANCE INFORMAT atient's MEDICAL and PRESCRIPT				
Primary Insurance Name:			one Number:		
Primary Insurance ID:					
	SSMENT **Please			vith referral form.**	
Diagnosis (ICD-10 Code):		Date Migraines started: Nun		nber of headache days per month:	
Previous Acute Migrain					
Name of drug and dose	Duration of therapy	Outcome (effective, suboptim intolerant, failed)		al, Discontinued (Y/N) - Reason?	
<b>Previous Prophylactic N</b> Name of drug and dose	<b>Migraine Medication</b> (last content of the state)         Duration of the state	st 3 months):	ctive, suboptimal, ed)	Discontinued (Y/N) - Reason?	
4 PRESCRIBER IN				NPI:	
Practice Address:		, ,		ate: Zip:	
		J		21p	
5 SITE OF INFUS If Infusion Clinic, please fill ou		Office	Infusion Clinic	Home	
				ate: Zip:	
nfusion Clinic Contact Name:		Phone:	En	nail:	

	VYEPTI PRESCRIPTION
/EPTI 100-mg	/mL single-use vial SIG: Infuse mg over 30 min once every 3 months Qty:(vials) Refills:
ended dose is 1	00mg IV every 3 months. Some patients may benefit from Vyepti 300mg IV every 3 months. Supplied as Vypeti 100mg/ml – 1 ml vial)
	HOME INFUSION/NURSING ORDERS (please check box if patient is infusing in the home)
	• Skilled Nursing Visit: As needed for IV access, drug administration and clinical monitoring.
	<ul> <li>Provide necessary infusion and flush supplies (e.g. tubing).</li> </ul>
	<ul> <li>Infusion instructions:</li> <li>Use 10ml NS flush to establish line patency</li> </ul>
	<ul> <li>Dilute in 100ml 0.9% Sodium Chloride Inj, USP.</li> </ul>
	Use an infusion set with 0.2 micron or 0.22 micron in-line or add-on sterile filter.
	<ul> <li>After infusion, flush IV line with 20ml of 0.9% NaCl.</li> </ul>
	INFUSION REACTION MANAGEMENT ORDERS (complete these items as appropriate.)
	INFUSION REACTION MANAGEMENT ORDERS (complete these items as appropriate.)
	sion reaction occurs STOP drug infusion and start 0.9% saline 250ml- administer at 50ml/h
once i	sion reaction occurs STOP drug infusion and start 0.9% saline 250ml- administer at 50ml/h
once i 2. CALL I	sion reaction occurs STOP drug infusion and start 0.9% saline 250ml- administer at 50ml/h nfusion stops
once i 2. CALL I 3. ADMI	sion reaction occurs STOP drug infusion and start 0.9% saline 250ml- administer at 50ml/h nfusion stops PRESCRIBER at:

7 PHYSICIAN SIGNATURE (Required)							
X		Х					
PRODUCT SUBSTITUTION PERMITTED	Date of Signature	DISPENSE AS WRITTEN	Date of Signature				
IMPORTANT NOTICE: This facsimile transmission is intended to be del anyone other than the named addressee, the recipient should imme be read or retained by anyone other than the named addressee, exce	vered only to the named addressee and may contain liately notify the sender at the address and telephone of by express authority of the sender to the named ad	material that is confidential, privileged, proprietary or exempt from disc number set forth herein and obtain instructions as to disposal of the tra fressee.	losure under applicable law. If it is received by ansmitted material. In no event should such material				
anyone other than the named addressee, the recipient should imme be read or retained by anyone other than the named addressee, exce	liately notify the sender at the address and telephone ot by express authority of the sender to the named ad	number set forth herein and obtain instructions as to disposal of the tra dressee.	insmitted material. In no event should such				

## 8 PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH INFORMATION

(Signature and Date Requirement)

By signing below, I authorize my healthcare providers (including pharmacies and infusion providers) and health plans (together, my "Heath Team") to disclose my personal health information relevant to my treatment or potential treatment with VYEPTI® (eptinezumab-jjmr), including my contact and other information provided on this enrollment form (my "Information"), to Lundbeck LLC and it's affiliates, agents, representatives, and service providers (collectively, "Lundbeck"), so that Lundbeck can undertake the activities listed below that involve the use and disclosure of my information.

I authorize Lundbeck to share my information with my Health Team to communicate about my benefit and coverage status and my medical care and payments for my medical treatment, and to use my information to: (1) administer the VYEPTI Patient Support Program(s) I enroll in (collectively, the "Programs"), as applicable; (2) provide me with patient support, including facilitating the provision of VYEPTI to me; (3) provide me with information and promotional materials relating to Lundbeck products and/or my condition or treatment; (4) contact me for Program or research purposes or to provide the information about Lundbeck products and services, including by phone, email and/or text message, and including through messages that disclose that I take or may take VYEPTI; and (5) allow Lundbeck to analyze the usage patterns and the effectiveness of Lundbeck products, support, and programs, and for other Lundbeck general business and administrative purposes. I understand that Lundbeck may compensate my pharmacy providers for communicating with me about the benefits of Lundbeck products or services, and I authorize my pharmacy providers to make such communications.

I understand that I am not required to sign this Authorization in order to receive healthcare benefits or treatment, including with Lundbeck products. I also understand that once my information has been disclosed to Lundbeck, federal privacy laws may no longer restrict its disclosure and it might legally be redisclosed to others.

I understand that I may cancel this authorization at any time by sending a written cancellation notice to 1111 Nicholas BLVD, Elk Grove Village, IL 60007, attention, Privacy Office. I understand that if I were to cancel the authorization, it would be invalid for further uses and disclosures of my Information, but that my cancellation would not invalidate any uses and disclosures of my Information made prior to the Program's receipt of my notice of withdrawal. I understand that if I do not cancel this authorization, the authorization will expire ten years from the date of signature (or the maximum period allowed by applicable state laws, if less than ten years. I understand that I am entitled to receive a copy of this authorization once it has been signed.

Print Patient/Authorized Contact Name:							
Relationship to Patient:	Self	Spouse	Other:				
Patient Cell Phone:			Patient Email:				
Х							
PATIENT/AUTHORIZED CONTACT SIGNATURE					DATE OF SIGNATURE		